Moleculin Biotech, a Houston-based clinical-stage pharmaceutical company, focuses on developing treatments for tumors and viruses with three core technologies and six drug candidates. Established in 2016, it employs 18 people and has candidates showing human activity in trials.
Walter V Klemp sold 1,351,350 shares of MBRX on 23 June at $0.00 per share, worth a total of $0. They now own 2,409,481 MBRX shares, or a 65% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
